• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes.使用氯喹进行COVID-19临床试验的驱动因素：选择正确研究问题和结果的必要性。
Rev Soc Bras Med Trop. 2020 Apr 6;53:e20200155. doi: 10.1590/0037-8682-0155-2020. eCollection 2020.
2
Death threats after a trial on chloroquine for COVID-19.一项关于氯喹治疗新冠肺炎的试验后出现死亡威胁。
Lancet Infect Dis. 2020 Jun;20(6):661. doi: 10.1016/S1473-3099(20)30383-2.
3
Chloroquine for COVID-19 Infection.氯喹用于新型冠状病毒肺炎感染
Drug Saf. 2020 May;43(5):393-394. doi: 10.1007/s40264-020-00933-4.
4
Of chloroquine and COVID-19.关于氯喹和 COVID-19。
Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5.
5
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.在 COVID-19 大流行期间使用羟氯喹和氯喹：每个临床医生都应该知道的事。
Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.
6
Chloroquine and hydroxychloroquine in covid-19.氯喹和羟氯喹在2019冠状病毒病中的应用
BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
7
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.抗2019冠状病毒病（COVID-19）的氨基喹啉：氯喹或羟氯喹。
Int J Antimicrob Agents. 2020 Apr;55(4):105945. doi: 10.1016/j.ijantimicag.2020.105945. Epub 2020 Mar 17.
8
Chloroquine and COVID-19, where do we stand?氯喹与新型冠状病毒肺炎，我们目前的情况如何？
Med Mal Infect. 2020 May;50(3):229-230. doi: 10.1016/j.medmal.2020.03.004. Epub 2020 Mar 27.
9
Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.2019年冠状病毒病（COVID-19）与抗风湿药物
Rheumatol Int. 2020 May;40(5):825-826. doi: 10.1007/s00296-020-04570-z. Epub 2020 Mar 30.
10
Combating COVID-19 with Chloroquine.用氯喹抗击新冠病毒。
J Mol Cell Biol. 2020 May 18;12(4):249-250. doi: 10.1093/jmcb/mjaa015.

引用本文的文献

1
Study of Microbial Infections and Some Immunological Parameters among Covid-19 in ICU Patients in Najaf Governorate, Iraq.伊拉克纳杰夫省 ICU 患者中 COVID-19 相关微生物感染和部分免疫参数研究。
Arch Razi Inst. 2022 Oct 31;77(5):1569-1574. doi: 10.22092/ARI.2022.358102.2151. eCollection 2022 Oct.
2
Metabolomic Profiling of Plasma Reveals Differential Disease Severity Markers in COVID-19 Patients.血浆代谢组学分析揭示COVID-19患者疾病严重程度的差异标志物
Front Microbiol. 2022 Apr 27;13:844283. doi: 10.3389/fmicb.2022.844283. eCollection 2022.
3
Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.慢性使用羟氯喹并未在巴西的一大群风湿疾病患者中预防 COVID-19。
Adv Rheumatol. 2021 Oct 7;61(1):60. doi: 10.1186/s42358-021-00217-0.
4
Brazil's Actions and Reactions in the Fight Against COVID-19 from January to March 2020.巴西 2020 年 1 月至 3 月抗击新冠肺炎疫情的行动与反应。
Int J Environ Res Public Health. 2021 Jan 11;18(2):555. doi: 10.3390/ijerph18020555.
5
Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences.针对新型冠状病毒的治疗选择：最新临床与实验室证据
Front Med (Lausanne). 2020 Sep 15;7:546. doi: 10.3389/fmed.2020.00546. eCollection 2020.
6
Pharmaceutical nanotechnology: which products are been designed against COVID-19?药物纳米技术：哪些产品正在针对新冠病毒进行设计？
J Nanopart Res. 2020;22(9):276. doi: 10.1007/s11051-020-05010-6. Epub 2020 Sep 9.
7
Drug repurposing and cytokine management in response to COVID-19: A review.药物再利用和细胞因子管理以应对 COVID-19：综述。
Int Immunopharmacol. 2020 Nov;88:106947. doi: 10.1016/j.intimp.2020.106947. Epub 2020 Aug 31.
8
Contributions of Latin American researchers in the understanding of the novel coronavirus outbreak: a literature review.拉丁美洲研究人员在理解新型冠状病毒爆发方面的贡献：文献综述
PeerJ. 2020 Jun 4;8:e9332. doi: 10.7717/peerj.9332. eCollection 2020.
9
Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.关于重新定位氯喹和羟氯喹用于治疗新冠病毒病的观点。
Sudan J Paediatr. 2020;20(1):4-9. doi: 10.24911/SJP.106-1587122398.
10
Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?我们是否有足够的证据将氯喹/羟氯喹用作应对新冠病毒病的公共卫生万能药？
Clinics (Sao Paulo). 2020;75:e1928. doi: 10.6061/clinics/2020/e1928. Epub 2020 May 8.

本文引用的文献

1
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
2
Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings.CT检查结果持续呈阴性的无症状新型冠状病毒感染患者。
Eur J Radiol. 2020 May;126:108956. doi: 10.1016/j.ejrad.2020.108956. Epub 2020 Mar 12.
3
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
4
SARS-CoV-2 Infection in Children.儿童感染新型冠状病毒2型
N Engl J Med. 2020 Apr 23;382(17):1663-1665. doi: 10.1056/NEJMc2005073. Epub 2020 Mar 18.
5
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
6
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
7
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
8
A novel coronavirus outbreak of global health concern.一场引发全球卫生关注的新型冠状病毒疫情。
Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24.
9
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
10
Adaptive Designs for Clinical Trials.临床试验的适应性设计
N Engl J Med. 2016 Jul 7;375(1):65-74. doi: 10.1056/NEJMra1510061.

Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes.

作者信息

Monteiro Wuelton Marcelo, Brito-Sousa Jose Diego, Baía-da-Silva Djane, Melo Gisely Cardoso de, Siqueira André Machado, Val Fernando, Daniel-Ribeiro Cláudio Tadeu, Guimarães Lacerda Marcus Vinicius

机构信息

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Departamento de Ensino e Pesquisa, Manaus, AM, Brasil.

Universidade do Estado do Amazonas, Programa de Pós-Graduação em Medicina Tropical, Manaus, AM, Brasil.

出版信息

Rev Soc Bras Med Trop. 2020 Apr 6;53:e20200155. doi: 10.1590/0037-8682-0155-2020. eCollection 2020.

DOI:10.1590/0037-8682-0155-2020
PMID:32267301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7156252/
Abstract
摘要